Research News
Another disease-modifying Alzheimer's therapy hits the market.
On June 10, the Food and Drug Administration’s Peripheral and Central Nervous System Drugs Advisory Committee unanimously voted that Eli Lilly’s Alzheimer’s drug, donanemab, is effective for treating early symptomatic Alzheimer’s disease.
A new BrightFocus-funded glaucoma vision research study suggests that Black and Asian people receive a critical glaucoma screening test less frequently than others, which could delay sight-saving treatment.
A new BrightFocus-funded study found that identifying disruptive sleep patterns may help identify people at risk of Alzheimer’s disease up to seven years prior to end of life.
A new BrightFocus study is revolutionizing our understanding of the eye through research on choroidal blood flow, potentially unlocking future treatments for macular degeneration.
A promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury, known risk factors for dementia, has received approval from the U.S. Food & Drug Administration to move into Phase 2 clinical trials. Learn more.
Learn how our funded scientists are advancing new ways of diagnosing Alzheimer’s disease earlier and more accurately.
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
